


1632
JW

TRANSMITTAL LETTER
(General - Patent Pending)

Docket No.
02940139AA

In Re Application Of: Schmidt-Ullrich, et al.



Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
09/714,790	November 17, 2000	Priebe	30743	1632	3995

Title: **GENETIC INHIBITION OF EPIDERMAL GROWTH FACTOR RECEPTOR FUNCTION AND
CARCINOMA CELL RADIOSENSITIZATION**

COMMISSIONER FOR PATENTS:


Transmitted herewith is:

INFORMATION DISCLOSURE STATEMENT; PTO 1449; 4 DOCS; FEE \$180.00

in the above identified application.

- No additional fee is required.
- A check in the amount of \$180.00 is attached.
- The Director is hereby authorized to charge and credit Deposit Account No. 50-2041 as described below.
 - Charge the amount of
 - Credit any overpayment.
 - Charge any additional fee required.
- Payment by credit card. Form PTO-2038 is attached.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.


Dated: December 29, 2004

Ruth Tyler-Cross

Reg No. 45,922

Whitham, Curtis & Christofferson, P.C.
11491 Sunset Hills Road, Suite 340
Reston, Virginia 20190
703-787-9400

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on _____.

(Date)

Signature of Person Mailing Correspondence

HAND DELIVERED

Typed or Printed Name of Person Mailing Correspondence

cc:



02940139AA

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re patent application of

Schmidt-Ullrich, et al.

Serial No.: 09/714,790

Group Art Unit: 1632

Filed: November 17, 2000

Examiner: Priebe

For: GENETIC INHIBITION OF EPIDERMAL GROWTH FACTOR RECEPTOR
FUNCTION AND CARCINOMA CELL RADIOSENSITIZATION

Commissioner of Patents and Trademarks
P. O. Box 1450
Alexandria, Virginia 22313

INFORMATION DISCLOSURE STATEMENT

Sir:

Under the provisions of 37 C.F.R. §1.97 through §1.99 and pursuant to applicant's duty of disclosure under 37 C.F.R. §1.56, applicant respectfully brings the following documents, listed on the attached form PTO-1449, to the attention of the Examiner in charge of the above-identified application. Copies of the listed documents are provided herewith for the convenience of the Examiner.

This citation does not constitute an admission that the references are relevant or material to the claims. They are only cited as constituting related art of which the applicant is aware.

12/30/2004 NNGUYEN1 00000076 09714790

01 FC:1806


180.00 OP

02940139AA

It is respectfully requested that the listed references be considered by the Examiner and formally made of record in this application.


A check for \$180.00 is submitted herewith. Please charge any deficiencies in fees and credit any overpayment of fees to Attorney's Deposit Account No. 50-2041.

Respectfully submitted,



Ruth Tyler-Cross
Registration No.: 45,922

Whitham, Curtis & Christofferson, P.C.
11491 Sunset Hills Road, Suite 340
Reston, Virginia 20190
703-787-9400
Customer Number: 30743


INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)

DEC 29 2004

Docket Number (Optional)

02940139AA

Application Number

09/714,790

Applicant(s)

Schmidt-Ullrich, et al.

Filing Date

November 17, 2000

Group Art Unit

1632
U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

U.S. PATENT APPLICATION PUBLICATIONS

*EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
						YES	NO


OTHER DOCUMENTS
(Including Author, Title, Date, Pertinent Pages, Etc.)

RADIATION-INDUCED ACTIVATION OF A COMMON VARIANT OF EGFR CONFFERS ENHANCED RADIRESISTANCE; G. Lammering, et al., Radiotherapy & Oncology 72, (2004) 267-273, Department of Radiation Oncology, Medical College of Virginia, Virginia Commonwealth University, Richmond, Va.

INHIBITION OF THE TYPE II EPIDERMAL GROWTH FACTOR RECEPTOR VARIANT MUTANT RECEPTOR BY DOMINANT-NEGATIVE EGFR-CD533 ENHANCES MALIGNANT GLIOMA CELL RADIOSensitivity, G. Lammering, et al., Clinical Cancer Research, Vol. 10, 6732-6743, October 1, 2004, Department of Radiation Oncology, Medical College of Virginia, Virginia Commonwealth University, Richmond, Virginia

EXAMINER
DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


INFORMATION DISCLOSURE CITATION
(use several sheets if necessary)

Docket Number (Optional)
02940139AA

Application Number
09/714,790

Applicant(s)
Schmidt-Ullrich, et al.

Filing Date

November 17, 2000

Group Art Unit

1632
U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

U.S. PATENT APPLICATION PUBLICATIONS

*EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
							YES	NO

OTHER DOCUMENTS
(Including Author, Title, Date, Pertinent Pages, Etc.)

EXTRACELLULAR DOMAINS DRIVE HOMO- BUT NOT HETERO-DIMERIZATION OF erbB RECEPTORS, K. M. Ferguson, et al., The EMBO Journal, Vol. 19 no. 17 pp 4632-4643, 2000, Department of BioChemistry & Biophysics and Johnson Research Foundation, University of Pennsylvania School of Medicine

THE CRYSTAL STRUCTURE OF A TRUNCATED ErbB2 ECTODOMAIN REVEALS AN ACTIVE CONFORMATION, POISED TO INTERACT WITH OTHER ErbB RECEPTORS, T. P. J. Garrett, et al., Molecular Cell, Vol. 11, 495-505, February 2003.

EXAMINER
DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.